ACHV - Achieve Life Sciences completes target enrollment in late-stage smoking cessation study

Achieve Life Sciences (ACHV) announces that it has reached target enrollment of 750 adult smokers in the company's late-stage smoking cessation study of cytisinicline.The trial is designed to evaluate the smoking cessation effectiveness, safety, and tolerability of 3 mg cytisinicline taken three times daily ((TID)) for either 6 or 12 weeks and will be compared with placebo.The primary outcome measure of success in the trial is biochemically verified continuous abstinence during the last four weeks of treatment in either the 6 or 12-week cytisinicline treatment arms as compared with placebo.Topline data results are expected to be reported within the first half of 2022.Shares up more than 1% premarket.

For further details see:

Achieve Life Sciences completes target enrollment in late-stage smoking cessation study